Marie Bosslett, Assistant Editor

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in hidradenitis suppurativa this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in atopic dermatitis this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in prurigo nodularis this year.

These promising results align with what was discovered in the single-ascending dose portion of the trial earlier this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in rosacea this year.

In case you missed it, this week we had news about tapinarof’s FDA approval in AD patients 2 and older, new ICD-10 codes for CCCA and FFA, a phase 2 study of INF904, and more.

Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a Dermatology Times custom video series.

Trust and transparency are key in physician wealth management, according to David Mandell, JD, MBA.

Follow-up phase 3 data showed BF-200 ALA to be a safe and effective therapy for AK, when compared to placebo.

The new research identified notable improvements in disease severity, sweat reduction, and quality of life for patients treated with sofpironium.

In a meta-analysis of over 61 million participants, it was found that AD patients have a 37% risk of developing IBD and similar conditions.

The latest publication from OJM Group provides 7 core strategies for dermatologists looking to meet their financial goals.

Take a look back at this year's newly FDA-approved dermatology devices and drugs.

Topical treatments with plant extracts improved skin hydration and elasticity while reducing melanin and erythema.

The approval is based on positive data stemming from the ADORING clinical trial program.

The supplemental New Drug Application is supported by positive results from the INTEGUMENT-PED and INTEGUMENT-OLE trials.

In case you missed it, this week we had news about the 308 nm excimer light and 2940 erbium laser for vitiligo, the new Diamond technique for the neck and décolleté, potential risk factors for developing CHE in China, and more.

Frequencies of 1/3/10 MHz and 3/10/19 MHz provided pain-free, well-tolerated, and long-lasting results.

The adalimumab biosimilar had an average persistence of 2.5 years, according to this British study.

In Middle Eastern communities specifically, patients with higher disease severity and duration are predicted to have poorer psychological outcomes.

The study found that those who worked with wet hands and had chapped skin had a higher severity of chronic hand eczema.

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

Although further trials are needed, this multidimensional, minimally invasive approach showed positive results in 4 patients.

The effect of insurance status on US patients with psoriasis can help identify those at risk of being undertreated.

Researchers noted higher correlations in those who are prone to severe acne and post acne erythema (PAE).

Graber spoke with Dermatology Times to share the top clinical pearls and key takeaways from the recent meetings.

With high clinician and participant satisfaction ratings, VYC-17.5 L was found to be safe and effective in reducing the appearance of marionette lines.

In case you missed it, this week we had news about the FDA-approval of Yesintek for psoriasis treatment, APG777 clinical trial updates, our inaugural Horizons in Advanced Practice meeting, and more.

Certain dermoscopic features in cutaneous warts may be associated with a favorable cryotherapy response.